All In Biotech

Investigational drug · Phase 2

S095024

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-small Cell Lung Cancer (NSCLC).

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "S095024"

First trial start

2024

Aug 7, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "S095024", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Non-small Cell Lung Cancer (NSCLC)

Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "S095024" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Non-small Cell Lung Cancer (NSCLC)

  • SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials

    Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer

  • AdebrelimabSHR-8068, HRS -4642Phase 341 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors

  • TiragolumabMTIG7192A, RO7092284Phase 311 trials

    Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer

  • Rina-SPRO1184, GEN1184Phase 39 trials

    Genmab · Ovarian Cancer, Platinum-resistant Ovarian Cancer, Endometrial Cancer

  • Merck & Co. · Esophageal Squamous Cell Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma

  • AtebimetinibIMM-1-104, Group APhase 34 trials

    Immuneering Corporation · Pancreatic Adenocarcinoma, Advanced Solid Tumor, Malignant Melanoma (Cutaneous)

  • H2 receptor antagonistPhase 34 trials

    Merck & Co. · Lung Neoplasm Malignant, Esophageal Squamous Cell Carcinoma, Ovarian Cancer

  • H1 receptor antagonistPhase 33 trials

    Merck & Co. · Lung Neoplasm Malignant, Ovarian Cancer, Fallopian Tube Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.